Clinical study of deep sedation with remazolam in radiofrequency catheter ablation of atrial fibrillation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048630

Enrollment

Unknown

Registered

2021-07-12

Start date

2021-07-15

Completion date

Unknown

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radiofrequency ablation of atrial fibrillation

Interventions

group1:remazolam

Group 2:No

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Patients with atrial fibrillation scheduled to receive elective catheter radiofrequency ablation; 2.Patients were between 18 and 70 years old.

Exclusion criteria

Exclusion criteria: 1. Anticipated airway difficulty; 2. BMI>=35; 3. ASA>=III grade; 4. Have a history of allergy to benzodiazepines.

Design outcomes

Primary

Measure	Time frame
Adverse respiratory events;	—

Countries

China

Contacts

Public ContactZhang Wei

The First Affiliated Hospital of Zhengzhou University

chalou666666@126.com+86 13838390767

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026